Chronic neutrophilic leukemia natural history, compilications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) |
Homa Najafi (talk | contribs) |
||
| Line 18: | Line 18: | ||
===Natural History=== | ===Natural History=== | ||
*The symptoms of CNL usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | *The symptoms of CNL usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | ||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | *If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
===Complications=== | ===Complications=== | ||
*The common complications of CNL include:<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref> | *The common [[complications]] of CNL include:<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref> | ||
** Predisposing to hemorrhage (intracranial hemorrhage as the most common cause of death in CNL patients) | ** Predisposing to [[hemorrhage]] ([[intracranial hemorrhage]] as the most common cause of death in CNL [[patients]]) | ||
** Progression of disease | ** Progression of disease | ||
** Blastic or leukemic conversion | ** Blastic or [[leukemic]] conversion | ||
** Treatment-related toxicity | ** Treatment-related [[toxicity]] | ||
===Prognosis=== | ===Prognosis=== | ||
Progression to acute myeloid leukemia may seen in 10-21.2% of patients with CNL.<ref name="Elliott2006">{{cite journal|last1=Elliott|first1=Michelle A.|title=Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined|journal=Best Practice & Research Clinical Haematology|volume=19|issue=3|year=2006|pages=571–593|issn=15216926|doi=10.1016/j.beha.2005.07.012}}</ref><ref name="Reilly2002">{{cite journal|last1=Reilly|first1=John T.|title=CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?|journal=British Journal of Haematology|volume=116|issue=1|year=2002|pages=10–18|issn=0007-1048|doi=10.1046/j.1365-2141.2002.03234.x}}</ref> | * [[Progression]] to [[acute myeloid leukemia]] may seen in 10-21.2% of patients with CNL.<ref name="Elliott2006">{{cite journal|last1=Elliott|first1=Michelle A.|title=Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined|journal=Best Practice & Research Clinical Haematology|volume=19|issue=3|year=2006|pages=571–593|issn=15216926|doi=10.1016/j.beha.2005.07.012}}</ref><ref name="Reilly2002">{{cite journal|last1=Reilly|first1=John T.|title=CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?|journal=British Journal of Haematology|volume=116|issue=1|year=2002|pages=10–18|issn=0007-1048|doi=10.1046/j.1365-2141.2002.03234.x}}</ref> | ||
Prognosis is generally poor, and the 5-year survival rate of patients with CNL is approximately 28%.<ref name="Reilly2002">{{cite journal|last1=Reilly|first1=John T.|title=CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?|journal=British Journal of Haematology|volume=116|issue=1|year=2002|pages=10–18|issn=0007-1048|doi=10.1046/j.1365-2141.2002.03234.x}}</ref><ref>{{Cite journal | * [[Prognosis]] is generally poor, and the 5-year [[survival rate]] of patients with CNL is approximately 28%.<ref name="Reilly2002">{{cite journal|last1=Reilly|first1=John T.|title=CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?|journal=British Journal of Haematology|volume=116|issue=1|year=2002|pages=10–18|issn=0007-1048|doi=10.1046/j.1365-2141.2002.03234.x}}</ref><ref>{{Cite journal | ||
| author = [[J. Bohm]] & [[H. E. Schaefer]] | | author = [[J. Bohm]] & [[H. E. Schaefer]] | ||
| title = Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease | | title = Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease | ||
| Line 42: | Line 41: | ||
}}</ref> | }}</ref> | ||
*The factors that can predict poor outcomes are:<ref name="DaoTyner2017">{{cite journal|last1=Dao|first1=Kim-Hien T.|last2=Tyner|first2=Jeffrey W.|last3=Gotlib|first3=Jason|title=Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia|journal=Current Hematologic Malignancy Reports|volume=12|issue=5|year=2017|pages=432–441|issn=1558-8211|doi=10.1007/s11899-017-0413-y}}</ref><ref name="ElliottPardanani2015">{{cite journal|last1=Elliott|first1=Michelle A.|last2=Pardanani|first2=Animesh|last3=Hanson|first3=Curtis A.|last4=Lasho|first4=Terra L.|last5=Finke|first5=Christy M.|last6=Belachew|first6=Alem A.|last7=Tefferi|first7=Ayalew|title=ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia|journal=American Journal of Hematology|volume=90|issue=7|year=2015|pages=653–656|issn=03618609|doi=10.1002/ajh.24031}}</ref><ref>{{Cite journal | *The factors that can [[Prediction|predict]] poor [[outcomes]] are:<ref name="DaoTyner2017">{{cite journal|last1=Dao|first1=Kim-Hien T.|last2=Tyner|first2=Jeffrey W.|last3=Gotlib|first3=Jason|title=Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia|journal=Current Hematologic Malignancy Reports|volume=12|issue=5|year=2017|pages=432–441|issn=1558-8211|doi=10.1007/s11899-017-0413-y}}</ref><ref name="ElliottPardanani2015">{{cite journal|last1=Elliott|first1=Michelle A.|last2=Pardanani|first2=Animesh|last3=Hanson|first3=Curtis A.|last4=Lasho|first4=Terra L.|last5=Finke|first5=Christy M.|last6=Belachew|first6=Alem A.|last7=Tefferi|first7=Ayalew|title=ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia|journal=American Journal of Hematology|volume=90|issue=7|year=2015|pages=653–656|issn=03618609|doi=10.1002/ajh.24031}}</ref><ref>{{Cite journal | ||
| author = [[Massimo Breccia]], [[Francesca Biondo]], [[Roberto Latagliata]], [[Ida Carmosino]], [[Franco Mandelli]] & [[Giuliana Alimena]] | | author = [[Massimo Breccia]], [[Francesca Biondo]], [[Roberto Latagliata]], [[Ida Carmosino]], [[Franco Mandelli]] & [[Giuliana Alimena]] | ||
| title = Identification of risk factors in atypical chronic myeloid leukemia | | title = Identification of risk factors in atypical chronic myeloid leukemia | ||
| Line 53: | Line 52: | ||
| pmid = 17043019 | | pmid = 17043019 | ||
}}</ref> | }}</ref> | ||
** white blood cell count>50,000 cells per microliter | ** [[White blood cells|white blood cell]] count>50,000 [[cells per microliter]] | ||
** ASXL1 mutation | ** [[ASXL1]] [[mutation]] | ||
** Thrombocytopenia | ** [[Thrombocytopenia]] | ||
** Advanced age | ** [[Advanced age]] | ||
** Dependency to transfusion | ** Dependency to [[transfusion]] | ||
** Peripheral | ** Peripheral [[blast]]<nowiki/>s ≥ 1% | ||
** Marrow blasts ≥ 10% | ** [[Marrow]] blasts ≥ 10% | ||
** Splenomegaly | ** [[Splenomegaly]] | ||
*The indication of disease progression in CNL patients include:<ref name="DaoTyner2015">{{cite journal|last1=Dao|first1=K.-H. T.|last2=Tyner|first2=J. W.|title=What's different about atypical CML and chronic neutrophilic leukemia?|journal=Hematology|volume=2015|issue=1|year=2015|pages=264–271|issn=1520-4391|doi=10.1182/asheducation-2015.1.264}}</ref> | *The indication of disease progression in CNL [[patients]] include:<ref name="DaoTyner2015">{{cite journal|last1=Dao|first1=K.-H. T.|last2=Tyner|first2=J. W.|title=What's different about atypical CML and chronic neutrophilic leukemia?|journal=Hematology|volume=2015|issue=1|year=2015|pages=264–271|issn=1520-4391|doi=10.1182/asheducation-2015.1.264}}</ref> | ||
** Treatment-resistant | ** Treatment-resistant | ||
** Refractory neutrophilia | ** [[Refractory]] [[neutrophilia]] | ||
** Increasing in red blood cells | ** Increasing in [[Red blood cell|red blood cells]] | ||
** Platelet transfusion dependency | ** [[Platelet transfusions|Platelet transfusion]] dependency | ||
** Deterioration of organomegaly | ** Deterioration of [[organomegaly]] | ||
** Blast crisis | ** [[Blast crisis]] | ||
==References== | ==References== | ||
Revision as of 17:54, 21 January 2019
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia natural history, compilications and prognosis On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia natural history, compilications and prognosis |
|
FDA on Chronic neutrophilic leukemia natural history, compilications and prognosis |
|
CDC on Chronic neutrophilic leukemia natural history, compilications and prognosis |
|
Chronic neutrophilic leukemia natural history, compilications and prognosis in the news |
|
Blogs on Chronic neutrophilic leukemia natural history, compilications and prognosis |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of CNL usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- The common complications of CNL include:[1][2]
- Predisposing to hemorrhage (intracranial hemorrhage as the most common cause of death in CNL patients)
- Progression of disease
- Blastic or leukemic conversion
- Treatment-related toxicity
Prognosis
- Progression to acute myeloid leukemia may seen in 10-21.2% of patients with CNL.[3][4]
- Prognosis is generally poor, and the 5-year survival rate of patients with CNL is approximately 28%.[4][5]
- The factors that can predict poor outcomes are:[6][7][8]
- white blood cell count>50,000 cells per microliter
- ASXL1 mutation
- Thrombocytopenia
- Advanced age
- Dependency to transfusion
- Peripheral blasts ≥ 1%
- Marrow blasts ≥ 10%
- Splenomegaly
- The indication of disease progression in CNL patients include:[9]
- Treatment-resistant
- Refractory neutrophilia
- Increasing in red blood cells
- Platelet transfusion dependency
- Deterioration of organomegaly
- Blast crisis
References
- ↑ Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
- ↑ Cigudosa, Juan C; Menezes, Juliane (2015). "Chronic neutrophilic leukemia: a clinical perspective". OncoTargets and Therapy: 2383. doi:10.2147/OTT.S49688. ISSN 1178-6930.
- ↑ Elliott, Michelle A. (2006). "Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined". Best Practice & Research Clinical Haematology. 19 (3): 571–593. doi:10.1016/j.beha.2005.07.012. ISSN 1521-6926.
- ↑ 4.0 4.1 Reilly, John T. (2002). "CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?". British Journal of Haematology. 116 (1): 10–18. doi:10.1046/j.1365-2141.2002.03234.x. ISSN 0007-1048.
- ↑ J. Bohm & H. E. Schaefer (2002). "Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease". Journal of clinical pathology. 55 (11): 862–864. PMID 12401827. Unknown parameter
|month=ignored (help) - ↑ Dao, Kim-Hien T.; Tyner, Jeffrey W.; Gotlib, Jason (2017). "Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia". Current Hematologic Malignancy Reports. 12 (5): 432–441. doi:10.1007/s11899-017-0413-y. ISSN 1558-8211.
- ↑ Elliott, Michelle A.; Pardanani, Animesh; Hanson, Curtis A.; Lasho, Terra L.; Finke, Christy M.; Belachew, Alem A.; Tefferi, Ayalew (2015). "ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia". American Journal of Hematology. 90 (7): 653–656. doi:10.1002/ajh.24031. ISSN 0361-8609.
- ↑ Massimo Breccia, Francesca Biondo, Roberto Latagliata, Ida Carmosino, Franco Mandelli & Giuliana Alimena (2006). "Identification of risk factors in atypical chronic myeloid leukemia". Haematologica. 91 (11): 1566–1568. PMID 17043019. Unknown parameter
|month=ignored (help) - ↑ Dao, K.-H. T.; Tyner, J. W. (2015). "What's different about atypical CML and chronic neutrophilic leukemia?". Hematology. 2015 (1): 264–271. doi:10.1182/asheducation-2015.1.264. ISSN 1520-4391.